1. Home
  2. GBDC vs RCUS Comparison

GBDC vs RCUS Comparison

Compare GBDC & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Golub Capital BDC Inc.

GBDC

Golub Capital BDC Inc.

N/A

Current Price

$13.22

Market Cap

3.4B

Sector

Finance

ML Signal

N/A

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

N/A

Current Price

$29.79

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GBDC
RCUS
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.6B
IPO Year
2009
2018

Fundamental Metrics

Financial Performance
Metric
GBDC
RCUS
Price
$13.22
$29.79
Analyst Decision
Strong Buy
Buy
Analyst Count
4
10
Target Price
$14.38
$31.90
AVG Volume (30 Days)
1.1M
1.2M
Earning Date
05-04-2026
05-05-2026
Dividend Yield
11.69%
N/A
EPS Growth
4.41
N/A
EPS
0.29
N/A
Revenue
N/A
$247,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$45.62
P/E Ratio
$45.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.77
$10.07
52 Week High
$14.93
$31.74

Technical Indicators

Market Signals
Indicator
GBDC
RCUS
Relative Strength Index (RSI) 55.55 56.83
Support Level $12.70 $25.94
Resistance Level $13.45 $31.41
Average True Range (ATR) 0.23 1.20
MACD 0.01 0.13
Stochastic Oscillator 70.00 62.68

Price Performance

Historical Comparison
GBDC
RCUS

About GBDC Golub Capital BDC Inc.

Golub Capital BDC Inc. is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in U.S. middle-market companies. It also invests in second-lien and subordinated loans, warrants, and minority equity securities in U.S. middle-market companies. The company generally invests in securities rated below investment grade by independent rating agencies, or those that would be rated below investment grade if evaluated. The company operates in the USA, Canada, and other countries, with the majority of its revenue coming from the USA.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Share on Social Networks: